Core Viewpoint - Nanjing Weilizhibo Biotechnology Co., Ltd. (referred to as "Weilizhibo") successfully listed on the Hong Kong Stock Exchange, opening at HKD 72.40 and closing at HKD 67.10, marking a 91.71% increase from its final offering price of HKD 35.00 [1][2][3] Group 1: Company Overview - Weilizhibo is a clinical-stage biotechnology company focused on discovering, developing, and commercializing new therapies for cancer, autoimmune diseases, and other major diseases [1] - The company issued a total of 36,862,500 H-shares, with 16,027,200 shares allocated for public offering in Hong Kong and 20,835,300 shares for international offering [2][3] Group 2: Financial Details - The total proceeds from the offering amounted to HKD 1,290.2 million, with net proceeds of HKD 1,179.3 million after deducting estimated listing expenses of HKD 110.8 million [2][3] - The net proceeds are intended for clinical development of candidate drugs, advancing preclinical assets, enhancing production capacity, and general corporate purposes [3] Group 3: Performance Metrics - For the fiscal year ending December 31, 2023, Weilizhibo reported revenues of RMB 8.9 million, with net losses of RMB 362.2 million [7][8] - The company’s cash flow from operating activities for the same period was a net outflow of RMB 192.7 million [9]
维立志博募12.9亿港元首日涨92% 去年零收入亏损3亿